Evidence map›Paper›PMID 36206498›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023

Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01).

Zhijie Wang, Lin Wu, Baolan Li, Ying Cheng, Xiaoling Li, Xicheng Wang, Liang Han, Xiaohong Wu, Yun Fan, Yan Yu and 57 more

Open access · bronzeAbstract readRandomized Controlled TrialMulticenter StudyClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 125 papers, 20 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
125citing papers in PubMed, 20 pooled it
23.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

125 citing papers in PubMed, 20 syntheses or guidelines pooled it, 164 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Pooled it

65 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

67 authors at 20 institutions in 2 countries.

Zhijie WangCAMS Key Laboratory of Translational Research on Lung Cancer, State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Lin WuHunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.ORCID 0000-0001-7078-7767
Baolan LiBeijing Chest Hospital, Capital Medical University, Beijing, China.
Ying ChengJilin Cancer Hospital, Changchun, China.ORCID 0000-0001-9908-597X
Xiaoling LiLiaoning Cancer Hospital & Institute, Shenyang, China.
Xicheng WangThe First Affiliated Hospital, School of Clinical Medicine of Guangdong Pharmaceutical University, Guangzhou, China.
Liang HanXuzhou Central Hospital, Xuzhou, China.
Xiaohong WuJiangnan University Affiliated Hospital, Wuxi, China.
Yun FanCancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China.
Yan YuHarbin Medical University Cancer Hospital, Harbin, China.
Dongqing LvTaizhou Hospital of Zhejiang Province, Linhai, China.
Jianhua ShiLinyi Cancer Hospital, Linyi, China.
Jianjin HuangThe Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Shaozhang ZhouGuangxi Medical University Affiliated Tumor Hospital, Nanning, China.
Baohui HanShanghai Chest Hospital, Shanghai, China.
Guogui SunTangshan People's Hospital, Tangshan, China.
Qisen GuoShangdong Cancer Hospital, Jinan, China.
Youxin JiQingdao Central Hospital, Qingdao, China.
Xiaoli ZhuZhongda Hospital Southeast University, Nanjing, China.
Sheng HuHubei Cancer Hospital, Wuhan, China.
Wei ZhangThe First Affiliated Hospital of Nanchang University, Nanchang, China.
Qiming WangHenan Cancer Hospital, Zhengzhou, China.ORCID 0000-0002-7813-2885
Yuming JiaThe Second People's Hospital of Yibin, Yibin, China.
Ziping WangPeking University Cancer Hospital, Beijing, China.
Yong SongJinling Hospital, Nanjing University School of Medicine, Nanjing, China.
Jingxun WuThe First Affiliated Hospital of Xiamen University, Xiamen, China.
Meiqi ShiJiangsu Cancer Hospital, Nanjing, China.
Xingya LiThe First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zhigang HanAffiliated Tumor Hospital of Xinjiang Medical University, Urumqi, China.
Yunpeng LiuThe First Hospital of China Medical University, Shenyang, China.
Zhuang YuThe Affiliated Hospital of Qingdao University, Qingdao, China.ORCID 0000-0003-1676-135X
An-Wen LiuThe Second Affiliated Hospital of Nanchang University, Nanchang, China.
Xiuwen WangQilu Hospital of Shandong University, Jinan, China.
Caicun ZhouShanghai Pulmonary Hospital, Shanghai, China.
Diansheng ZhongTianjin Medical University General Hospital, Tianjin, China.
Liyun MiaoAffiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China.ORCID 0000-0001-9586-3244
Zhihong ZhangAnhui Provincial Cancer Hospital, Hefei, China.
Hui ZhaoThe Second Hospital of Anhui Medical University, Hefei, China.
Jun YangThe Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Dong WangArmy Medical Center of PLA, Daping Hospital, Daping, China.
Yingyi WangPeking Union Medical College Hospital, Beijing, China.
Qiang LiShanghai East Hospital of Tongji University, Shanghai, China.
Xiaodong ZhangNantong Tumor Hospital, Nantong, China.
Mei JiThe First People's Hospital of Changzhou, Changzhou, China.
Zhenzhou YangThe Second Affiliated Hospital of Chongqing University, Chongqing, China.
Jiuwei CuiThe First Hospital of Jilin University, Jilin, China.
Beili GaoRuijin Hospital Shanghai Jiaotong University, School of Medicine, Shanghai, China.
Buhai WangSubei People's Hospital of Jiangsu Province, Yanghzou, China.
Hu LiuAnhui Provincial Cancer Hospital, Hefei, China.ORCID 0000-0001-6774-6868
Lei NieShanxi Provincial Tumor Hospital, Xian, China.
Mei HeShanxi Provincial People's Hospital, Taiyuan, China.ORCID 0000-0003-4502-6362
Shi JinCancer Hospital of Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen, China.
Wei GuNanjing First Hospital, Nanjing, China.ORCID 0000-0002-3705-9845
Yongqian ShuThe First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Tong ZhouChangZhou Cancer Hospital, Changzhou, China.
Jian FengAffiliated Hospital of Nantong University, Nantong, China.
Xinmei YangJiaxing No. 1 Hospital, Jiaxing, China.
Cheng HuangFujian Cancer Hospital, Fuzhou, China.
Bo ZhuXinqiao Hospital of Army Medical University, Chongqing, China.
Yu YaoFirst Affiliated Hospital of Xi'an Jiaotong University, Xian, China.
Xiongwen TangTopAlliance Biosciences, Rockville, MD.ORCID 0000-0002-5930-5197
Jianjun YuTopAlliance Biosciences, Rockville, MD.
Ellen MaherTopAlliance Biosciences, Rockville, MD.
Hui FengTopAlliance Biosciences, Rockville, MD.
Sheng YaoTopAlliance Biosciences, Rockville, MD.ORCID 0000-0003-0988-9937
Patricia KeeganTopAlliance Biosciences, Rockville, MD.ORCID 0000-0002-7266-395X
Jie WangCAMS Key Laboratory of Translational Research on Lung Cancer, State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.ORCID 0000-0002-5602-0487
Chinese Academy of Medical Sciences & Peking Union Medical College · CNBioReliance (United States) · USBioscience (China) · CNAnhui Provincial Hospital · CNArmy Medical University · CNFirst Affiliated Hospital of Zhengzhou University · CNGuangdong Pharmaceutical University · CNNanchang University · CNQingdao University · CNAnhui Medical University · CNCancer Hospital of Chinese Academy of Medical Sciences · CNCapital Medical University · CNCentral South University · CNChongqing University · CNFirst Affiliated Hospital of Xiamen University · CNFirst Affiliated Hospital of Xi'an Jiaotong University · CNFirst Hospital of China Medical University · CNFirst Hospital of Jiaxing · CNFujian Provincial Cancer Hospital · CNHangzhou Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe CHOICE-01 study investigated the efficacy and safety of toripalimab in combination with chemotherapy as a first-line treatment for advanced non-small-cell lung cancer (NSCLC). PATIENTS AND

methodsPatients (N = 465) with treatment-naive, advanced NSCLC without

resultsAt the final PFS analysis, PFS was significantly longer in the toripalimab arm than in the placebo arm (median PFS, 8.4

conclusionToripalimab plus chemotherapy significantly improves PFS and OS in patients with treatment-naive advanced NSCLC while having a manageable safety profile. Subgroup analysis showed the OS benefit was mainly driven by the nonsquamous subpopulation.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsHumansPhosphatidylinositol 3-KinasesAntibodies, Monoclonal, HumanizedPhosphatidylinositol 3-Kinasestoripalimab

Identifiers

PMID36206498
PMCPMC9870236
OpenAlexW4303488453

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.